Clinical trial NCT02046369: Lurasidone Pediatric Bipolar Study
Official title: A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bipolar I Depression
Keywords: Lurasidone, Latuda, Bipolar Depression
Lead sponsor: Sumitomo Pharma America, Inc.
Sponsor class: INDUSTRY
First posted: 2014-01-27
Enrollment: 350
Sex: ALL
Minimum age (years): 10
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression

Detailed description: This is a randomized, parallel, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of flexibly dosed lurasidone (20 - 80 mg/day) for 6 weeks compared with placebo in children and adolescent subjects with depression associated with Bipolar I Disorder (bipolar depression).

Eligibility criteria: Inclusion Criteria:

* Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' adherence to the study procedures must be obtained for subjects who are not emancipated. If emancipated, subjects must provide written informed consent. In accordance with Institutional Review Board (IRB) requirements, the subject will complete an informed assent prior to study participation.

  * Male or female subjects 10 to 17 years of age, inclusive with bipolar I disorder, most recent episode depressed, with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but \< 8 episodes in the previous 12 months) and without psychotic features (diagnosed by DSM-V criteria, and confirmation of the bipolar I disorder diagnosis by an adequately trained clinician at the time of screening, by means of the Schedule for Affective Disorders and Schizophrenia for School-age Children \[K-SADS-PL\]). Note: The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records.
  * Subject has a lifetime history of at least one manic episode. A reliable informant (eg, family member or caregiver) or medical records must be able to confirm this history.
  * Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration.
  * CDRS-R score ≥ 45 at screening and Baseline.
  * YMRS score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at screening and Baseline.
  * Within 3rd to 97th percentile for gender specific BMI-for-age growth charts from the World Health Organization (WHO) growth charts
  * In good physical health on the basis of medical history, physical examination, and laboratory screening.
  * Females who participate in this study:

    * are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
    * practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
    * are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
  * Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
  * In the judgment of the investigator, the subject is able to swallow the size and number of study drug tablets specified per protocol
  * Willing and able to adhere to protocol-specified meal requirements during dosing.
  * Subjects may have a lifetime diagnosis of ADHD. If a subject is taking psychostimulants for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. This must be confirmed by the investigator and noted in the source records.

Exclusion Criteria:

* Has an Axis I or Axis II (DSM-IV or any DSM-5) diagnosis other than bipolar I disorder that has been the primary focus of treatment within 3 months of screening.
* Subject has been hospitalized for a bipolar manic or mixed episode within the 30 days prior to randomization.
* Has a history or current diagnosis of intellectual disability, autism spectrum disorder, neuroleptic malignant syndrome, or any neurologic disorder, or severe head trauma.
* Lifetime history of human immunodeficiency virus (HIV) positive or acquired immune deficiency syndrome (AIDS), or history of Hepatitis B or C.
* Any of the following:
* Documented history of chromosomal disorder with developmental impairment (ie, trisomy chromosome 21; 22q11 deletion syndrome).
* Evidence of any chronic organic disease of the CNS such as tumors, inflammation, active seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood - eg, Duchenne muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders. In addition, subjects must not have a history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is not exclusionary.
* CDRS-R total score \> 85 at screening or Baseline
* Demonstrates a decrease (improvement) of ≥ 25% in the CDRS-R adjusted total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline.
* Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
* Lifetime history of electroconvulsive therapy (ECT).
* Resistant to antipsychotic treatment based on at least two prior adequate trials (ie, adequate dose and duration) of an antipsychotic agent within the current episode of depression, or subject has a history of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode.
* Clinically significant neurological, metabolic (including Type 1 diabetes), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, carcinoma, and/or urological disorder that would pose a risk to the subjects if they were to participate in the study or that might confound the results of the study.
* Has a history of malignancy \< 5 years prior to signing the informed consent.
* Clinically significant finding(s) on physical examination determined by the investigator to pose a health concern to the subject while on study.
* Clinically relevant abnormal laboratory values or abnormal vital sign values/findings.
* A history or presence of abnormal ECG, which in the investigator's opinion is clinically significant. Abnormal screening ECGs will be centrally over-read, and eligibility will be determined based on the over-read.
* Presence or history (within the last year) of a medical or surgical condition (eg, gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
* Clinically significant substance abuse disorder (with the exception of caffeine or tobacco) based on DSM-5 criteria within the last 6 months prior to screening.
* Positive test results at screening or Baseline for:

  1. Urine drugs of abuse (including amphetamines/methamphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine, and cannabinoids). A positive test for amphetamines/methamphetamines, barbiturates, opioids, or benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed. In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the investigator will evaluate the subject's ability to abstain from prohibited substances during the study. If in the investigator's clinical judgment the subject will abstain, the subject may be enrolled after consultation with the Medical Monitor.
  2. Pregnancy test.
* Females who are pregnant, lactating, or likely to become pregnant during the study.
* Participated in another interventional clinical trial or receiving an investigational product within 30 days prior to screening.
* Donation of whole blood within 60 days prior to randomization.
* Known history or presence of clinically significant intolerance to any antipsychotic medications including but not limited to angioedema, serotonin or neuroleptic malignant syndromes.
* Clinically relevant history of drug hypersensitivity to lurasidone or any components in the formulation.
* Use of concomitant medications that consistently prolong the QT/QTc interval within 28 days prior to randomization.
* Received depot neuroleptics unless the last injection was at least 1 month or 1 treatment cycle prior to screening, whichever is longer.
* Received treatment with antidepressants, atomoxetine or alpha 2 agonists (eg, guanfacine) within 3 days prior to randomization, fluoxetine hydrochloride within 21 days of randomization, monoamine oxidase (MAO) inhibitor within 28 days of randomization, or clozapine within 120 days of randomization.
* Use of all psychotropic medications prior to randomization with the exception of those medications explicitly permitted within 3 days prior to randomization (7 days prior to randomization for aripiprazole).
* Has a prolactin concentration ≥ 100 ng/mL at screening, or has a history of pituitary adenoma.
* At screening or Baseline the subject answers "yes" to "Suicidal Ideation" Items 4 or 5 on the C-SSRS or has a score of 7 on item 13, Suicidal Ideation, on the CDRS-R.
* Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property during the study. Subject has a history of one or more serious suicide attempts (based on the investigator's judgment) in the 3 months prior to screening. Subjects determined to be at risk of suicide or injury, as assessed by the investigator at screening, will be referred for further psychiatric evaluation.
* Adhering to a special diet for the 28 days prior to drug administration (eg, liquid, protein, raw food diet).
* Subject is planning to move during the study, is chronically homeless, or is unable to attend all planned study visits. The Medical Monitor will be consulted for individual cases, as needed.
* Subject with newly diagnosed Type 2 diabetes during screening or subject is on injectable medication for the treatment of Type 2 diabetes. A subject with Type 2 diabetes is eligible for study inclusion if considered clinically stable, which is defined as:

  * Random (non-fasting) screening glucose is \< 200 mg/dl (11.1 mmol/L); and If ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state. Retested fasted value cannot be ≥ 126 mg/dL.
  * HbA1c ≤ 6.5%; and
* If a subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to screening. Such medication may be adjusted or discontinued during the study, as clinically indicated.
* Subject has required hospitalization for diabetes or related complications in the past 12 months.
* The use of concomitant medications that are potent inducers or inhibitors of the cytochrome P450 (CYP) 3A4 enzyme system during the trial (from signing informed consent until follow-up).
* Clinically significant orthostatic hypotension (ie, a drop in systolic blood pressure of 20 mmHg or more and/or drop in diastolic blood pressure of 10 mmHg or more within 4 minutes of standing up).

Primary outcomes:
measure: Change in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score as Compared to Placebo From Double-Blind Baseline to Week 6 (Day 43) Baseline
timeFrame: baseline, Week 6
Secondary outcomes:
measure: Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Score as Compared to Placebo.
timeFrame: baseline and week 6
measure: Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Score as Compared to Placebo.
timeFrame: baseline
measure: Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score as Compared to Placebo.
timeFrame: baseline and week 6
measure: Change From Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Score as Compared to Placebo.
timeFrame: baseline and week 6
measure: Change From Baseline in Clinical Global Impressions-Bipolar-Severity (CGI-BP-S) Depression Score
timeFrame: baseline and week 6
Other outcomes:
Locations:
city: Dothan
country: United States
facility: Harmonex Neuroscience Research
state: Alabama
city: Culver City
country: United States
facility: ProScience Research Group
state: California
city: Hartford
country: United States
facility: Hartford Hospital
state: Connecticut
city: Gainesville
country: United States
facility: Sarkis Clinical Trials - Parent
state: Florida
city: Orlando
country: United States
facility: APG Research, LLC
state: Florida
city: Atlanta
country: United States
facility: Atlanta Center for Medical Research
state: Georgia
city: Smyrna
country: United States
facility: Attalla Consultants, LLC
state: Georgia
city: Libertyville
country: United States
facility: Capstone Clinical Research, Inc.
state: Illinois
city: Overland Park
country: United States
facility: Psychiatric Associates
state: Kansas
city: Lake Charles
country: United States
facility: Lake Charles Clinical Trials, LLC
state: Louisiana
city: Baltimore
country: United States
facility: Kennedy Krieger Institute
state: Maryland
city: Bloomfield Hills
country: United States
facility: Neurobehavioral Medicine Group, PLLC
state: Michigan
city: Saint Charles
country: United States
facility: St. Charles Psychiatric Associates
state: Missouri
city: Neptune
country: United States
facility: Jersey Shore University Medical Center
state: New Jersey
city: Glen Oaks
country: United States
facility: North Shore/Long Island Jewish PRIME
state: New York
city: Mount Kisco
country: United States
facility: Bioscience Research, LLC
state: New York
city: Rochester
country: United States
facility: Finger Lakes Clinical Research
state: New York
city: Staten Island
country: United States
facility: Richmond Behavioral Associates
state: New York
city: Cincinnati
country: United States
facility: University of Cincinnati Medical Center
state: Ohio
city: Cleveland
country: United States
facility: University Hospitals Case Medical Center
state: Ohio
city: Oklahoma City
country: United States
facility: Cutting Edge Research of Enid
state: Oklahoma
city: Memphis
country: United States
facility: Research Strategies of Memphis, LLC
state: Tennessee
city: Austin
country: United States
facility: BioBehavioral Research of Austin
state: Texas
city: Dallas
country: United States
facility: Pillar Clinical Research, LLC
state: Texas
city: The Woodlands
country: United States
facility: Family Psychiatry of The Woodlands, P.A.
state: Texas
city: Clinton
country: United States
facility: Ericksen Research & Development, LLC
state: Utah
city: Orem
country: United States
facility: Aspen Clinical Research
state: Utah
city: Charlottesville
country: United States
facility: University of Virginia
state: Virginia
city: Petersburg
country: United States
facility: Clinical Research Partners, LLC
state: Virginia
city: Bothell
country: United States
facility: Pacific Institute Of Medical Sciences
state: Washington
city: Ruse
country: Bulgaria
facility: MHC - Ruse, EOOD
city: Targovishte
country: Bulgaria
facility: MHAT-Targovishte, AD
city: Varna
country: Bulgaria
facility: DCC "Mladost M" - Varna, OOD
city: Barranquilla
country: Colombia
facility: Centro de Investigaciones y Proyectos en Neurociencias CIPNA
city: Bogota
country: Colombia
facility: Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
city: Nice
country: France
facility: Hôpitaux Pédiatriques de Nice CHU-Lenval
state: Alpes Maritimes
city: Nantes Cedex 1
country: France
facility: CHU Nantes - Hôpital Mère-Enfant
city: Budapest
country: Hungary
facility: Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
city: Gyula
country: Hungary
facility: Bekes Megyei Pandy Kalman Korhaz
city: Jeonju
country: Korea, Republic of
facility: Chonbuk National University Hospital
state: Jeollabuk-do
city: Gwangju
country: Korea, Republic of
facility: Chonnam National University Hospital
state: Jeollanam-do
city: Incheon
country: Korea, Republic of
facility: Inha University Hospital
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
city: Monterrey
country: Mexico
facility: Accelerium S. de R.L. de C.V.
state: Nuevo León
city: Culiacan
country: Mexico
facility: Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
city: Durango
country: Mexico
facility: Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
city: Monterrey
country: Mexico
facility: Instituto de Informacion de Investigacion en Salud Mental
city: San Luis Potosí
country: Mexico
facility: Consultorio Especializado Psiquiatría Infantil y Adolescentes
city: Iloilo City
country: Philippines
facility: West Visayas State University Medical Center
city: Mandaluyong City
country: Philippines
facility: National Center for Mental Health
city: Quezon City
country: Philippines
facility: Veterans Memorial Medical Center
city: Kobierzyce
country: Poland
facility: NZOZ Poradnia Zdrowia Psychicznego
city: Torun
country: Poland
facility: Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu
city: Warsawa
country: Poland
facility: Instytut Psychiatrii i Neurologii
city: San Juan
country: Puerto Rico
facility: INSPIRA Clinical Research
city: Ivano Frankivsk
country: Ukraine
facility: RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
city: Kharkiv
country: Ukraine
facility: SI Institute of Neurology, Psychiatry and Narcology of NAMSU
city: Kharkiv
country: Ukraine
facility: SI Institute of Children and Adolescents Healthcare of NAMSU
city: Kherson
country: Ukraine
facility: CI Kherson Regional Psychiatric Hospital of Kherson RC
city: Lviv
country: Ukraine
facility: CI Lviv Regional Clinical Psychiatric Hospital
city: Odesa
country: Ukraine
facility: CI Odesa Regional Medical Center of Mental Health
city: Poltava
country: Ukraine
facility: O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
city: Ternopil
country: Ukraine
facility: Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
city: Vinnytsia
country: Ukraine
facility: Chair of Psychiatry and Narcology, Vinnytsia National Medical University, O.I. Yushchenko Regional Psychoneurological Hospital
Study officials:
affiliation: Sumitomo Pharma America, Inc.
name: Medical Director, MD
role: STUDY_DIRECTOR
References:
citation: DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1015-1025. doi: 10.1016/j.jaac.2017.10.006. Epub 2017 Oct 13.